Oncolytics Biotech (ONCY) Common Equity (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Common Equity of -$3.8 million for Q4 2025, down 188.7% year-over-year from $4.3 million in Q4 2024, and down 4646.27% quarter-over-quarter from $83563.0 in Q3 2025.
Oncolytics Biotech (ONCY) Common Equity (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Common Equity for 17 consecutive years, with -$3.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 188.7% year-over-year to -$3.8 million; the TTM figure through Dec 2025 stood at -$3.8 million (down 188.7% YoY), while the FY2025 annual figure was -$3.8 million, down 215.19% from the prior year.
- Common Equity retreated to -$3.8 million in Q4 2025 per ONCY's latest filing, from $83563.0 in the prior quarter.
- Across five years, Common Equity topped out at $37.8 million in Q2 2021 and bottomed at -$3.8 million in Q4 2025.
- Historically, Common Equity has averaged $17.6 million across 5 years, with a median of $19.3 million in 2022.
- Annual changes were most pronounced in 2021 — Common Equity jumped 61.8% — and 2025, when it tumbled 188.7%.
- Oncolytics Biotech's Common Equity stood at $28.6 million in 2021, then sank by 31.83% to $19.5 million in 2022, then advanced by 3.7% to $20.2 million in 2023, then slumped by 78.85% to $4.3 million in 2024, then sank by 188.7% to -$3.8 million in 2025.
- Business Quant data shows ONCY's Common Equity at -$3.8 million in Q4 2025, $83563.0 in Q3 2025, and $4.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Oncolytics Biotech | 96.23 Mn | 96.23 Mn | - | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.17 Mn |
| Dec 31, 2025 | -3.80 Mn |
| Sep 30, 2025 | 83,563.03 |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | 4.53 Mn |
| Dec 31, 2024 | 4.28 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Jun 30, 2024 | 13.39 Mn |
| Mar 31, 2024 | 17.05 Mn |
| Dec 31, 2023 | 20.25 Mn |
| Sep 30, 2023 | 21.65 Mn |
| Jun 30, 2023 | 16.56 Mn |
| Mar 31, 2023 | 19.05 Mn |
| Dec 31, 2022 | 19.52 Mn |
| Sep 30, 2022 | 21.77 Mn |
| Jun 30, 2022 | 24.14 Mn |
| Mar 31, 2022 | 27.64 Mn |
| Dec 31, 2021 | 28.64 Mn |
| Sep 30, 2021 | 33.93 Mn |
| Jun 30, 2021 | 37.82 Mn |